Drug Discovery & Pharma R&D

Drug discovery is the long, costly search for new medicines — finding a biological target, designing a molecule that acts on it, and validating safety and efficacy. Historically it takes well over a decade and billions of dollars to bring one drug to market, and most candidates fail along the way. The bottlenecks are scientific search problems at enormous scale, which is exactly where AI has made its most celebrated scientific contributions.

The landmark was protein-structure prediction: AlphaFold solved a problem that had stumped biology for fifty years, predicting the three-dimensional shape of essentially every known protein. That unlocked a wave of AI-driven discovery — generative models that design candidate molecules, platforms that run millions of virtual experiments, and lab-in-the-loop systems that learn from each round of testing. Work that took years of trial and error is increasingly done in software first, with only the most promising candidates moving to the bench.

AlphaFold predicts protein structures and, through DeepMind's drug spin-off Isomorphic Labs, now drives end-to-end drug design. Recursion Pharmaceuticals and Insilico Medicine run industrial-scale AI discovery platforms with candidates already in clinical trials, while Schrödinger brings physics-based simulation to molecular design. BenevolentAI mines biomedical literature for new targets, and Calico and Manas AI apply machine learning to longevity and oncology discovery. Together they span target finding, molecule design, and trial prediction.

AI is compressing the discovery phase of drug development from years toward months and raising the odds that a candidate survives to the clinic, which over time could lower the staggering cost of new medicines. The work shifts from manual screening toward designing and interpreting AI-driven experiments, raising the premium on scientists who can pair deep biology with computational fluency. The honest caveat is that discovery is only the front end — clinical trials still take years and most drugs still fail in human testing, so AI has accelerated the lab, not yet the clinic. But the first AI-designed drugs are now in trials, and that pipeline is the field's most-watched proof point.